Wall Street sees this chip stock as the big winner from the Anthropic IPO

D.A. Davidson upgraded Broadcom to Buy from Neutral and raised its price target to $400 from $350, implying nearly 22% upside, citing the potential Anthropic IPO and AI-chip demand. Broadcom said a special purpose vehicle will finance $63 billion in its AI chips for Anthropic; Anthropic has also disclosed plans to borrow up to $42 billion from Broadcom for AI infrastructure. Broadcom shares rose more than 3% premarket, though they were down nearly 5% year to date; 48 of 51 covering analysts rate the stock Buy or Strong Buy.

Analysis

The key underwriting issue is not the IPO itself; it is whether Anthropic can convert capital access into durable, funded chip orders without Broadcom absorbing disproportionate customer-credit risk. The financing supports near-term visibility, but financing a customer’s purchases can make demand look more certain while concentrating exposure to the same customer’s ability to raise capital and sustain infrastructure spending. Verify whether Broadcom’s stated lending commitment is transferred, secured, or otherwise limited before treating it as pure backlog de-risking.

Over days, the analyst upgrade and premarket move risk extending a crowded bullish narrative: 48 of 51 analysts are already positive, so incremental upside likely requires estimates to rise, not simply another endorsement. Over 1–3 months, monitor IPO progress, the final financing structure, and Broadcom commentary on customer orders and cash exposure. Over 6–18 months, the thesis depends on Anthropic deployments and monetization keeping pace with infrastructure commitments; a delayed listing, weaker funding demand, or capex reprioritization could expose the financing as a correlated downside rather than a backstop. The cited 2027 EPS multiple is an analyst’s framing, not independent confirmation of valuation.

Contrarian view: financing availability is not proof of attractive returns on AI infrastructure, and an IPO can broaden Anthropic’s funding options without guaranteeing that proceeds support the projected purchases. The supply-chain read-through is directionally positive but should not be generalized to all chip suppliers absent order evidence.

Key Decisions for Investors

• Do not chase the opening gap. Consider scaling into a modest AVGO position only after the initial reaction holds and financing terms clarify; the upside case relies on execution beyond already-bullish positioning.
• Treat confirmation of an effective transfer or limitation of Broadcom’s up-to-$42B financing exposure, alongside firm order or guidance evidence, as the 1–3 month add catalyst. If exposure remains concentrated, size the position as both an AI-demand and customer-credit risk.
• Falsify the thesis on a material delay or failure of the IPO/funding process, evidence of order deferrals, or Broadcom guidance that weakens the 2027–28 custom-chip outlook. Reassess rather than averaging down.
• Monitor Anthropic’s realized infrastructure deployment and funding use over 6–18 months; financing raised without corresponding deployments or durable customer economics would undermine the projected demand, even if the IPO succeeds.